SeekingAlpha · Sep 15, 2026
HQL: The Rally That Makes Growth Harder (Rating Downgrade)
HQL downgraded to Hold after big rally; 12.5% yield, NAV discount and payout risks weigh on upside.
HQ
NYSE · HQL
Tekla Life Sciences Investors
Financial Services · Asset Management
$17.56
Down-$0.12 (-0.68%)
Updated Oct 7, 2026, 11:07 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 497.33M
- P/E ratio
- -40.78
- Dividend yield
- 10.36%
- 52-week range
- $15.82 – $22.67
- Volume
- 186.92K
- Avg. volume
- 194.28K
Price performance · HQL
HQL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
HQL closed at $17.56 after 21 trading sessions, down 14.59% for the selected period.
- Last close
- $17.56
- Period change
- -14.59%
- Period low
- $17.56
- Period high
- $20.56
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $17.86 | $17.935 | $17.05 | $17.56 | 186.92K |
| Oct 5, 2026 | $17.70 | $17.74 | $17.1419 | $17.68 | 156.91K |
| Oct 2, 2026 | $18.20 | $18.285 | $17.60 | $17.68 | 245.72K |
| Oct 1, 2026 | $18.66 | $19.005 | $18.08 | $18.17 | 128.57K |
| Sep 30, 2026 | $18.60 | $19.2213 | $18.53 | $18.70 | 92.43K |
| Sep 29, 2026 | $18.91 | $18.91 | $18.36 | $18.49 | 126.88K |
| Sep 28, 2026 | $18.87 | $18.9599 | $18.60 | $18.90 | 105.59K |
| Sep 25, 2026 | $19.46 | $19.46 | $18.875 | $18.97 | 122.53K |
| Sep 24, 2026 | $19.45 | $19.56 | $19.14 | $19.27 | 115.7K |
| Sep 23, 2026 | $19.87 | $20.20 | $19.49 | $19.56 | 131.28K |
| Sep 22, 2026 | $19.75 | $20.04 | $19.59 | $19.98 | 109.82K |
| Sep 21, 2026 | $19.52 | $19.66 | $19.4156 | $19.59 | 65.09K |
| Sep 18, 2026 | $19.57 | $19.7499 | $19.25 | $19.41 | 87.45K |
| Sep 17, 2026 | $19.50 | $19.7999 | $19.49 | $19.57 | 124.62K |
| Sep 16, 2026 | $19.44 | $19.56 | $19.16 | $19.28 | 159.15K |
| Sep 15, 2026 | $19.86 | $19.86 | $19.20 | $19.39 | 206.5K |
| Sep 14, 2026 | $19.76 | $19.8997 | $19.46 | $19.86 | 128.57K |
| Sep 11, 2026 | $19.86 | $19.96 | $19.59 | $19.76 | 134.32K |
| Sep 10, 2026 | $20.34 | $20.34 | $19.68 | $19.79 | 151.08K |
| Sep 9, 2026 | $20.62 | $20.67 | $20.29 | $20.34 | 92.93K |
| Sep 8, 2026 | $20.53 | $20.63 | $20.30 | $20.56 | 121.34K |
Latest HQL news
The latest Smart Investors Daily articles mentioning HQL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HQL research
Overview
Company profile and research snapshot.
Company profile
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 29, 2026
Abrdn Life Sciences Investors Q2 2026 Commentary
abrdn Life Sciences Investors (HQL) outperformed its benchmark as uniQure and Personalis posted strong gains. Read the full report for detailed performance data.
SeekingAlpha · Aug 13, 2026
abrdn Life Sciences Investors Q2 2026 Commentary
The equity portion of the Fund rose (gross of fees) and outperformed its benchmark, the NASDAQ Biotechnology Index. Read more here.
SeekingAlpha · Feb 25, 2026
Abrdn Life Sciences Investors Fund Q4 2025 Commentary
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
